Day: June 5, 2024

“Ford Amphitheater” will be the most luxurious amphitheater in the Nation Ten-year term struck between Notes Live, Inc. dba Venu Holding Corporation, and Ford CHARLOTTE, N.C., June 05, 2024 (GLOBE NEWSWIRE) — Fresh Vine Wine Inc. (NYSE American: VINE) (“Fresh Vine”) today announced that its merger partner live entertainment and hospitality company formally Notes Live, Inc. dba Venu Holding Corporation (“VENU”) struck a ten-year naming rights term with Colorado Ford Dealers to the new outdoor amphitheater in Colorado Springs, Colorado. On June 4, 2024 — Ford (NYSE: F) has acquired the naming rights to the ultra-lux outdoor music venue coming to Colorado Springs. The highly anticipated music haven owned by live entertainment and hospitality company formally Notes Live, Inc. dba Venu Holding Corporation (“Venu”), is set for its Grand...

  Conditions of availability of information and documents related to the General Meeting of June 26, 2024 Paris, June 5, 2024 – The General Meeting of the Company will be held on first notice on Wednesday, June 26th, 2024, at 3 p.m. (Paris time), at l’Espace 73 – 73, rue d’Anjou, 75008 Paris, France. The notice of meeting, including the agenda and the text of the draft resolutions, was published at the French official legal announcement publication (BALO) on May 17th, 2024, Bulletin 60, under number 2401823. The convening notice will be published at the BALO and in a French Journal d’annonces légales, on Monday, June 10th, 2024. The participation and voting conditions at this meeting are included in these two notices. Information and documents relating to the General Meeting required under article R. 225-83 of the French commercial...

June 5, 2024 Vantiva: Information concerning the total number of voting rights and shares, provided pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés FinanciersVantiva Shares(ISIN Code FR0013505062)Date Number of Outstanding Shares Number of Voting RightsMay 31, 2024   490,143,003     Number of Theoretical Voting Rights(1): 490,143,003    Number of Voting Rights Exercisable at Shareholders’ meeting(2): 490,143,003  (1)    Calculated, pursuant to Article 223-11 of the General Regulations of the Autorité des Marchés Financiers, based on the total number of outstanding shares to which voting rights are attached, including shares with suspended voting rights. (2)    Excluding shares with suspended voting rights. *                ** About Vantiva www.vantiva.com...

HSINCHU, Taiwan and EINDHOVEN, The Netherlands, June 05, 2024 (GLOBE NEWSWIRE) — Vanguard International Semiconductor Corporation (“VIS”, TPEx 5347) and NXP Semiconductors N.V. (“NXP”, NASDAQ: NXPI) today announce the plan to create a manufacturing joint-venture VisionPower Semiconductor Manufacturing Company Pte Ltd (“VSMC”) which will build a new 300mm semiconductor wafer manufacturing facility in Singapore. The joint-venture fab will support 130nm to 40nm mixed-signal, power management and analog products, targeting the automotive, industrial, consumer and mobile end markets. The underlying process technologies are planned to be licensed and transferred to the joint venture from TSMC. The joint venture will begin construction of the initial phase of the wafer fab in the second half of 2024, pending receipt of all required regulatory...

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The clinical poster presentations highlight the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) in both HBeAg-positive and HBeAg-negative subjects. Data from ≤72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment Of the patients who have stopped all therapy, six still have undetectable levels of HBsAg and HBV DNA, with two of these patients reaching 12 weeks off all therapy All six patients have seroconverted and have high titers of anti-HBsAg antibodies These new Phase 2a data were presented at the European Association for the Study of the Liver (EASL) Congress 2024 WARMINSTER, Pa., June 05, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

5 June 2024 ICG Enterprise Trust extends €240m revolving credit facility to 2028 ICG Enterprise Trust plc (‘ICGT’) is pleased to announce that it has extended the maturity of its €240m revolving credit facility (‘RCF’) by one year, from 30 May 2027 to 29 May 2028. There are no changes to any other key terms in the agreement as announced on 1 June 2023. At 31 May 2024, ICGT had total available liquidity of £166m (31 January 2024: £196m). This is comprised of £9m cash and £157m undrawn RCF. As of the same date, £59m was drawn on the RCF. Enquiries Analyst / Investor enquiries                                                                                                 Chris Hunt, Head of Shareholder Relations                 +44 (0) 20 3545 2000 Media                                                                                                               ...